GeneDx uses artificial intelligence and machine learning to analyze patient data to provide insights to transform the practice of medicine.
GeneDx has raised $150.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in January 2023.
GeneDx's investors include BlackRock, Connecticut Innovations, Oak HC/FT, Pfizer, Perceptive Advisors.
GeneDx is headquartered in Stamford, United States.
GeneDx uses artificial intelligence and machine learning to analyze patient data to provide insights to transform the practice of medicine.
GeneDx is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"GeneDx — Funding & Investors." VCBacked, January 26, 2023, https://www.vcbacked.co/company/genedx. Accessed August 14, 2026.
VCBacked. (2023). GeneDx — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/genedx
{{cite web |title=GeneDx — Funding & Investors |url=https://www.vcbacked.co/company/genedx |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated